![]() |
| Kris Wood, PhD, associate professor of Pharmacology and Cancer Biology |
After losing a close friend to an aggressive form of leukemia, acute myeloid leukemia (AML), Kris Wood, PhD, associate professor of pharmacology and cancer biology, devoted his research to helping find better treatment options for people with leukemias and lymphomas. He and his colleagues have discovered a potential new drug therapy that is preparing to enter clinical trials.
A new class of drugs called nuclear exportin inhibitors has recently been approved for use to treat cancers. Nuclear exportins are proteins that shuttle other proteins out of the nucleus of a cell. These new drugs stop the shuttle from leaving the station.
“The idea is that if you treat cells with a drug that blocks a nuclear exportin,” Wood said, “its client proteins become trapped in the nucleus.” And while researchers don’t fully understand why this is therapeutic, it works. Wood and his team investigated the mechanisms behind it. Their results were published in Nature Cancer.
First, they treated AML cells with Selinexor, a nuclear exportin inhibitor. At the same time, they used CRISPR screens to knock out thousands of genes across the genome one at a time to identify genes that made the drug work either much better or much worse when knocked out.














